ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 251.01 USD | +4.37% |
|
+4.35% | +6.67% |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development and Commercialization of Rnai Therapeutics | 220M | 493M | 844M | 1.04B | 1.83B | |||||
Total Assets | 2.4B | 3.41B | 3.64B | 3.55B | 3.83B | |||||
Interest Expense | - | -84.5M | -143M | -156M | -121M | |||||
Income Tax Expense | 863K | 2.68M | 680K | 4.16M | 6.72M | |||||
CAPEX | -140M | -70.36M | -76.37M | -72.06M | -62.21M | |||||
EBT | -885M | -856M | -852M | -1.13B | -434M | |||||
D&A | 54.37M | 74.44M | 89.69M | 85.55M | 97.03M | |||||
Operating Income | -939M | -828M | -709M | -785M | -282M | |||||
Net Income | -886M | -858M | -853M | -1.13B | -440M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 116M | 194M | 325M | 473M | 689M | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Europe | - | 120M | 260M | 315M | 399M | |||||
Rest of World | 50.08M | 47.06M | 77.03M | 107M | 153M |
- Stock Market
- Equities
- ALNY Stock
- Financials Alnylam Pharmaceuticals, Inc.
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition